Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cipla Ltd ( (IN:CIPLA) ).
Cipla’s U.S. subsidiary, Cipla USA Inc., has decided to initiate a recall of unexpired batches of Lanreotide Injection following discussions with Pharmathen International S.A. The move will result in a temporary lack of supply of this product to the market, signalling a short-term disruption for patients and healthcare providers relying on the drug while the company addresses the underlying issues and regulatory disclosure requirements.
More about Cipla Ltd
Cipla Ltd is an India-based global pharmaceutical company that develops and manufactures a broad range of generic and branded medicines. Through subsidiaries such as Cipla USA Inc., it supplies critical therapies to international markets, with a strong presence in regulated markets like the U.S. and Europe and a focus on accessible, affordable healthcare.
Average Trading Volume: 126,757
Technical Sentiment Signal: Buy
Current Market Cap: 1067.7B INR
Find detailed analytics on CIPLA stock on TipRanks’ Stock Analysis page.